NCT05082610 is a Phase 1 clinical trial of HMBD-002 in Cancer, sponsored by Hummingbird Bioscience.

Who is sponsoring NCT05082610?

NCT05082610 is sponsored by Hummingbird Bioscience.

What drugs are being tested in NCT05082610?

Interventions in NCT05082610: HMBD-002, Pembrolizumab.

What condition does NCT05082610 study?

NCT05082610 studies Cancer, Tumor, Solid, Nonsmall Cell Lung Cancer, Triple Negative Breast Cancer, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor.

Is NCT05082610 still recruiting?

NCT05082610 is currently completed. Last updated 16 October 2025.

Last reviewed 2025-10-16 · How we verify

NCT05082610

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Completed Phase 1 Last updated 16 October 2025

What this trial tests

Phase 1 trial testing HMBD-002 in Cancer in 48 participants. Completed in 3 December 2024.

Timeline

28 February 2022

Primary endpoint
5 November 2024

3 December 2024

Quick facts

Lead sponsor	Hummingbird Bioscience
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	28 February 2022
Primary completion	5 November 2024
Estimated completion	3 December 2024
Sites	6 locations across United States

Drugs / interventions tested

HMBD-002 — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →
Tumor, Solid — all drugs for Tumor, Solid →
Nonsmall Cell Lung Cancer — all drugs for Nonsmall Cell Lung Cancer →
Triple Negative Breast Cancer — all drugs for Triple Negative Breast Cancer →

Sponsor

Hummingbird Bioscience — full company profile →

Who can join

18 and older, any sex, with Cancer or Tumor, Solid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1/2, open-label, multi-center, first-in-human, two-stage (Part 1: dose escalation and Part 2: dose expansion) study evaluating multiple doses and schedules of intravenously (IV) administered HMBD-002, with or without pembrolizumab KEYTRUDA®, in patients with advanced solid tumors (i.e., locally advanced and unresectable, or metastatic).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
Niu Z, Jin R, Zhang Y, Li H. · · 2022 · cited 127× · PMID 36198685 · DOI 10.1038/s41392-022-01200-x
Recent Advances and Challenges in Cancer Immunotherapy.
Peterson C, Denlinger N, Yang Y. · · 2022 · cited 74× · PMID 36010965 · DOI 10.3390/cancers14163972
Immune checkpoint inhibitors: breakthroughs in cancer treatment.
Kong X, Zhang J, Chen S, Wang X, et al · · 2024 · cited 71× · PMID 38801082 · DOI 10.20892/j.issn.2095-3941.2024.0055
Clinical landscape of macrophage-reprogramming cancer immunotherapies.
Rannikko JH, Hollmén M. · · 2024 · cited 70× · PMID 38831013 · DOI 10.1038/s41416-024-02715-6
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment.
Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, et al · · 2023 · cited 58× · PMID 37345056 · DOI 10.3390/cancers15102718
Immune Checkpoint Inhibitors in Cancer Therapy-How to Overcome Drug Resistance?
Lao Y, Shen D, Zhang W, He R, et al · · 2022 · cited 53× · PMID 35892835 · DOI 10.3390/cancers14153575
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Emerging Trends in Immunotherapy for Cancer.
Mishra AK, Ali A, Dutta S, Banday S, et al · · 2022 · cited 41× · PMID 36135216 · DOI 10.3390/diseases10030060

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Hummingbird Bioscience trials

Trials by the same sponsor.

NCT05919537 — Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 F · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05082610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hummingbird Bioscience
Last refreshed: 16 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05082610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing